Literature DB >> 30647074

Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Hew Yeng Lai1, Stefan A Brooks1, Brianna M Craver1, Sarah J Morse2, Thanh Kim Nguyen2, Nahideh Haghighi3, Michael R Garbati4, Angela G Fleischman2,5.   

Abstract

Patients with myeloproliferative neoplasms (MPN) have high levels of inflammatory cytokines, some of which drive many of the debilitating constitutional symptoms associated with the disease and may also promote expansion of the neoplastic clone. We report here that monocytes from patients with MPN have defective negative regulation of Toll-like receptor (TLR) signaling that leads to unrestrained production of the inflammatory cytokine tumor necrosis factor α (TNF-α) after TLR activation. Specifically, monocytes of patients with MPN are insensitive to the anti-inflammatory cytokine interleukin 10 (IL-10) that negatively regulates TLR-induced TNF-α production. This inability to respond to IL-10 is a not a direct consequence of JAK2 V617F , as the phenotype of persistent TNF-α production is a feature of JAK2 V617F and wild-type monocytes alike from JAK2 V617F -positive patients. Moreover, persistent TNF-α production was also discovered in the unaffected identical twin of a patient with MPN, suggesting it could be an intrinsic feature of those predisposed to acquire MPN. This work implicates sustained TLR signaling as not only a contributor to the chronic inflammatory state of MPN patients but also a potential predisposition to acquire MPN.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30647074      PMCID: PMC6341195          DOI: 10.1182/bloodadvances.2018026450

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

1.  The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Authors:  Sylvie Hermouet; Mathias Vilaine
Journal:  Haematologica       Date:  2011-11       Impact factor: 9.941

2.  Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Authors:  Katerina E Panteli; Eleftheria C Hatzimichael; Paraskevi K Bouranta; Afroditi Katsaraki; Konstantinos Seferiadis; Justin Stebbing; Konstantinos L Bourantas
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

3.  Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA.

Authors:  Lisa Siewe; Mariela Bollati-Fogolin; Claudia Wickenhauser; Thomas Krieg; Werner Müller; Axel Roers
Journal:  Eur J Immunol       Date:  2006-12       Impact factor: 5.532

4.  Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma.

Authors:  D Stoiber; P Kovarik; S Cohney; J A Johnston; P Steinlein; T Decker
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness.

Authors:  Hitoshi Takizawa; Kristin Fritsch; Larisa V Kovtonyuk; Yasuyuki Saito; Chakradhar Yakkala; Kurt Jacobs; Akshay K Ahuja; Massimo Lopes; Annika Hausmann; Wolf-Dietrich Hardt; Álvaro Gomariz; César Nombela-Arrieta; Markus G Manz
Journal:  Cell Stem Cell       Date:  2017-07-20       Impact factor: 24.633

6.  Chronic exposure to a TLR ligand injures hematopoietic stem cells.

Authors:  Brandt L Esplin; Tomoyuki Shimazu; Robert S Welner; Karla P Garrett; Lei Nie; Qingzhao Zhang; Mary Beth Humphrey; Qi Yang; Lisa A Borghesi; Paul W Kincade
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

7.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

8.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  A novel function of interleukin-10 promoting self-renewal of hematopoietic stem cells.

Authors:  Young-Ju Kang; Seung-Jip Yang; Gyeongsin Park; Bin Cho; Chang-Ki Min; Tae-Yoon Kim; Joon-Sung Lee; Il-Hoan Oh
Journal:  Stem Cells       Date:  2007-04-26       Impact factor: 6.277

10.  Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.

Authors:  Malin Hultcrantz; Magnus Björkholm; Paul W Dickman; Ola Landgren; Åsa R Derolf; Sigurdur Y Kristinsson; Therese M L Andersson
Journal:  Ann Intern Med       Date:  2018-01-16       Impact factor: 25.391

View more
  13 in total

Review 1.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

2.  TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging.

Authors:  Pavel Davizon-Castillo; Brandon McMahon; Sonia Aguila; David Bark; Katrina Ashworth; Ayed Allawzi; Robert A Campbell; Emilie Montenont; Travis Nemkov; Angelo D'Alessandro; Nathan Clendenen; Lauren Shih; Natalie A Sanders; Kelly Higa; Allaura Cox; Zavelia Padilla-Romo; Giovanni Hernandez; Eric Wartchow; George D Trahan; Eva Nozik-Grayck; Kenneth Jones; Eric M Pietras; James DeGregori; Matthew T Rondina; Jorge Di Paola
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

Review 3.  Inflammation in Myeloid Malignancies: From Bench to Bedside.

Authors:  Eli M Soyfer; Angela G Fleischman
Journal:  J Immunother Precis Oncol       Date:  2021-07-14

Review 4.  The Microenvironment in Myeloproliferative Neoplasms.

Authors:  Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Hematol Oncol Clin North Am       Date:  2020-12-09       Impact factor: 3.722

5.  MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Min Wang; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

Review 6.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

7.  Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.

Authors:  Peter Müller; Conny K Baldauf; Tobias R Haage; Emmanouil Charakopoulos; Martin Böttcher; Vikas Bhuria; Dimitrios Mougiakakos; Burkhart Schraven; Thomas Fischer
Journal:  Hemasphere       Date:  2022-04-15

Review 8.  Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.

Authors:  Jonas Samuel Jutzi; Ann Mullally
Journal:  Front Immunol       Date:  2020-08-31       Impact factor: 7.561

9.  The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.

Authors:  Martina Barone; Lucia Catani; Francesca Ricci; Marco Romano; Dorian Forte; Giuseppe Auteri; Daniela Bartoletti; Emanuela Ottaviani; Pier Luigi Tazzari; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Oncoimmunology       Date:  2020-06-23       Impact factor: 8.110

10.  JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages.

Authors:  Rongqing Li; Na Sun; Xin Chen; Xueqin Li; Jie Zhao; Wanpeng Cheng; Hui Hua; Masahiko Fukatsu; Hirotaka Mori; Hiroshi Takahashi; Hiroshi Ohkawara; Miwa Fukami; Masatoshi Okamoto; Yoichi Hamazaki; Kuiyang Zheng; Jing Yang; Takayuki Ikezoe
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.